BioSpace News Archive

First Patient Enrolled in IPI-549 Plus OPDIVO® MDSC-High Cohort in Infinity Pharmaceuticals Ongoing IPI-549-01 Phase 1/1b Clinical Trial

SomaGenics announced the launch of RealSeq®-biofluids, a next-generation sequencing (NGS) library construction kit sensitive enough to detect small RNAs from cell-free biofluids. Further enhancing its efforts in the liquid biopsy arena, SomaGenics has received a 3-year Phase II SBIR grant from the NIH for the development of RealSeq®-T, a technology enabling extraction-free, targeted NGS of small RNAs directly from biofluids.

- Company to give two presentations at BIO International Convention in Boston June 4th - 7th, 2018: (i) Start-Up Stadium Finalist Presentation - Tuesday, June 5th from 3:15 - 3:30, Boston Convention Center, North Lobby; (ii) Company Presentation - Wednesday, June 6th from 2:15 - 2:30, Boston Convention Center, Theater 1 - Presentations to focus on dramatic increase in efficacy of locally-delivered cell therapies targeting solid tumors in preclinical models

The World Health Organization recommends IGRA tests in the First Edition of Essential In Vitro Diagnostics

The U.S.Food and Drug Administration (FDA) has issued warning letters to three marketers and distributors of kratom products.

Dr. Reddy’s Laboratories, Ltd. (BSE: 500124 | NSE: DRREDDY | NYSE: RDY) today announced its consolidated financial results for the fourth quarter and full year ended March 31, 2018 under International Financial Reporting Standards (IFRS).

Merck(NYSE:MRK), today announced that the Board of Directors has declared a quarterly dividend of $0.48 per share of the company’s common stock.

Avacta Group plc is pleased to announce that its research collaboration with FIT Biotech Oy.